S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44

NovaBay Pharmaceuticals (NBY) Stock Forecast, Price & News

0.00 (0.00%)
(As of 05/16/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
862,273 shs
Average Volume
454,901 shs
Market Capitalization
$9.98 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive NBY News and Ratings via Email

Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NovaBay Pharmaceuticals logo

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.


See More Headlines

Industry, Sector and Symbol

Stock Exchange
Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$9.93 million
Book Value
$0.29 per share


Net Income
$-11.03 million
Pretax Margin




Free Float
Market Cap
$9.98 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End


Overall MarketRank

1.86 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions

Is NovaBay Pharmaceuticals a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NovaBay Pharmaceuticals stock.
View analyst ratings for NovaBay Pharmaceuticals
or view top-rated stocks.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) posted its quarterly earnings data on Tuesday, March, 29th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter. The biopharmaceutical company had revenue of $2.64 million for the quarter. NovaBay Pharmaceuticals had a negative trailing twelve-month return on equity of 67.65% and a negative net margin of 96.77%.
View NovaBay Pharmaceuticals' earnings history

When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?

NovaBay Pharmaceuticals's stock reverse split on Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.

What price target have analysts set for NBY?

1 equities research analysts have issued 1 year price targets for NovaBay Pharmaceuticals' shares. Their forecasts range from $2.20 to $2.20. On average, they expect NovaBay Pharmaceuticals' stock price to reach $2.20 in the next year. This suggests a possible upside of 1,033.4% from the stock's current price.
View analysts' price targets for NovaBay Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are NovaBay Pharmaceuticals' key executives?
NovaBay Pharmaceuticals' management team includes the following people:
  • Mr. Justin M. Hall Esq., Pres, CEO, Gen. Counsel, Chief Compliance Officer, Corp. Sec. & Director (Age 44, Pay $400.52k)
  • Mr. Andrew D. Jones, CFO & Treasurer (Age 51, Pay $367.02k)
  • Dr. Audrey Kunin M.D., Chief Product Officer & Director (Age 63, Pay $202.82k)
  • Dr. Jeffrey Kunin M.D., Pres of DERMAdoctor (Age 59)
What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Bionano Genomics (BNGO), Heat Biologics (HTBX), iBio (IBIO), Matinas BioPharma (MTNB), Novan (NOVN), ADMA Biologics (ADMA) and Vaxart (VXRT).

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."

Who are NovaBay Pharmaceuticals' major shareholders?

NovaBay Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.39%). Company insiders that own NovaBay Pharmaceuticals stock include Andrew D Jones, Audrey Kunin, Jeffrey Kunin, Jian Ping Fu, Justin Hall and Mijia Wu.
View institutional ownership trends for NovaBay Pharmaceuticals

Which major investors are buying NovaBay Pharmaceuticals stock?

NBY stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought NovaBay Pharmaceuticals stock in the last two years include Andrew D Jones, Audrey Kunin, Jeffrey Kunin, and Justin Hall.
View insider buying and selling activity for NovaBay Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovaBay Pharmaceuticals' stock price today?

One share of NBY stock can currently be purchased for approximately $0.19.

How much money does NovaBay Pharmaceuticals make?

NovaBay Pharmaceuticals has a market capitalization of $9.98 million and generates $9.93 million in revenue each year. The biopharmaceutical company earns $-11.03 million in net income (profit) each year or ($0.17) on an earnings per share basis.

How many employees does NovaBay Pharmaceuticals have?

NovaBay Pharmaceuticals employs 22 workers across the globe.

What is NovaBay Pharmaceuticals' official website?

The official website for NovaBay Pharmaceuticals is novabay.com.

How can I contact NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at (510) 899-8800, via email at [email protected], or via fax at 510-474-1577.

This page was last updated on 5/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.